Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 283-286

  Inamoto, Yoshihiro ^a   Kurahashi, Shingo ^b   Imahashi, Nobuhiko ^c   Fukushima, Nobuaki ^d   Adachi, Tatsuya ^b   Kinoshita, Tomohiro ^a   Tsushita, Keitaro ^d   Miyamura, Koichi ^c   Naoe, Tomoki ^a   Sugiura, Isamu ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d CHUKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; RANIMUSTINE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CYTOGENETICS; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL SCORING SYSTEM; INTERPHASE; MAJOR CLINICAL STUDY; MALE; METAPHASE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 65649111249     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21390     Document Type: Article

References (22)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
2. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-534.
3. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495.
4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
5. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-150.
6. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
7. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575.
8. Rajkumar S, Fonseca R, Lacy M, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1999;24:497-503.
9. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004;64:1546-1558.
10. Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: High frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280-284.
11. Avet-Loiseau H, Brigaudeau C, Morineau N, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;24:9-15.
12. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-2028.
13. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
14. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856-863.
15. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
17. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
18. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157.
19. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120.
20. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
21. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.
22. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.